Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma

Completed · Phase 2

Conditions studied: Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin

In brief

This is a Phase II, open-label, multidose trial of SGN-40 designed to estimate objective response rate and assess toxicity in patients with relapsed DLBCL.

Key facts

Study ID

NCT00435916

Run by

Seagen Inc.

People needed

46

Starts

2006-12-01

Expected to finish

2009-01-01

Last updated by the study team

2015-01-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of DLBCL.
• Received at least one combination chemotherapy regimen with rituximab, such as R-CHOP, R-ESHAP or equivalent.
• Progression or relapse since most recent therapy.
• At least one measurable lesion that is both greater than or equal to 2 cm by conventional CT or greater than or equal to 1.5 cm by spiral CT.

You may not qualify if…

• Previous diagnosis or treatment for indolent lymphoma, leptomeningeal lymphoma, or central nervous system lymphoma.
• Primary refractory disease.
• Received an allogenic stem cell transplant.

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States
• Mayo Clinic-Arizona — Scottsdale, Arizona, United States
• University of California Los Angeles — Los Angeles, California, United States
• Stanford University Medical Center — Palo Alto, California, United States
• Sharp Healthcare — San Diego, California, United States
• Georgetown University — Washington D.C., District of Columbia, United States
• Northwestern University — Chicago, Illinois, United States
• Rush University Medical Center — Chicago, Illinois, United States
• Mayo Clinic-Rochester — Rochester, Minnesota, United States
• Washington University School of Medicine — St Louis, Missouri, United States
• Weill Medical College of Cornell University — New York, New York, United States
• Charleston Hematology Oncology Associates, PA — Charleston, South Carolina, United States
• Swedish Cancer Institute — Seattle, Washington, United States
• University of Wisconsin — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.